← Patent-cliff monitor small molecule AQVESME MITAPIVAT SULFATE
Loss of exclusivity July 2041 latest FDA-listed patent expiry
Drug detail Brand name AQVESME Active ingredient MITAPIVAT SULFATE Strength EQ 100MG BASE Dosage form TABLET Route ORAL Modality Small molecule FDA approval December 2025 Marketing status RX
Listed patents Patent Expires Type 11878049 July 2041 use U-4390 11254652 November 2038 substance, product RE49582 April 2035 substance, product 9193701 October 2032 use U-4393 10632114 May 2032 use U-4391 9682080 May 2032 use U-4392
Regulatory exclusivity Code Expires ODE-522 December 2032 NP December 2028 NCE February 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.